- Home
- BNRG vs JAGX Comparison
BNRG vs JAGX Comparison
Compare BNRG & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNRG
- JAGX
- Stock Information
- Founded
- BNRG 2012
- JAGX 2013
- Country
- BNRG Israel
- JAGX United States
- Employees
- BNRG N/A
- JAGX N/A
- Industry
- BNRG
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- BNRG
- JAGX Health Care
- Exchange
- BNRG Nasdaq
- JAGX Nasdaq
- Market Cap
- BNRG 5.2M
- JAGX 3.5M
- IPO Year
- BNRG 2022
- JAGX N/A
- Fundamental
- Price
- BNRG $2.59
- JAGX $2.53
- Analyst Decision
- BNRG
- JAGX Strong Buy
- Analyst Count
- BNRG 0
- JAGX 1
- Target Price
- BNRG N/A
- JAGX $60.00
- AVG Volume (30 Days)
- BNRG 143.6K
- JAGX 88.6K
- Earning Date
- BNRG 03-04-2025
- JAGX 08-12-2025
- Dividend Yield
- BNRG N/A
- JAGX N/A
- EPS Growth
- BNRG N/A
- JAGX N/A
- EPS
- BNRG N/A
- JAGX N/A
- Revenue
- BNRG N/A
- JAGX $11,552,000.00
- Revenue This Year
- BNRG N/A
- JAGX $22.41
- Revenue Next Year
- BNRG N/A
- JAGX $30.00
- P/E Ratio
- BNRG N/A
- JAGX N/A
- Revenue Growth
- BNRG N/A
- JAGX 13.93
- 52 Week Low
- BNRG $1.78
- JAGX $2.43
- 52 Week High
- BNRG $15.30
- JAGX $110.75
- Technical
- Relative Strength Index (RSI)
- BNRG 40.62
- JAGX 27.33
- Support Level
- BNRG $2.21
- JAGX $2.43
- Resistance Level
- BNRG $2.73
- JAGX $3.30
- Average True Range (ATR)
- BNRG 0.36
- JAGX 0.25
- MACD
- BNRG 0.05
- JAGX 0.06
- Stochastic Oscillator
- BNRG 39.30
- JAGX 4.65
About BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.